RxDoctor Payments DataLook up a doctor →

Barry Reiner

Pediatric Endocrinology · Baltimore, MDNPI 1386738938

Payments from drug & device makers

$1,457,756in general payments, 2019–2025

Across 1,646 payments — averaging $885.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$835K
  • Novo Nordisk AS$435K
  • Merck$77K
  • Medtronic$60K
  • Mannkind Corporation$40K
  • Grifols Therapeutics LLC$3K
  • plus $8K from 34 others
$652,058in research payments, 2019–2025

Across 1,103 payments — averaging $591.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$307K
  • Novo Nordisk AS$271K
  • Eli Lilly$60K
  • Daiichi Sankyo Inc.$14K

What the payments were for

  • Speaking & faculty fees$4,12528%
  • Travel & lodging$2,74518%
  • Food & beverage$7,74952%
  • Education$2051%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,457,756 in reported general payments places this provider in the 95th percentile of 33 pediatric endocrinology providers in Maryland.

See all pediatric endocrinology providers in Maryland

Most prescribed under Part D

DrugClaimsCost to plans & patients
OmnitropeSomatropin11$27,510
Levothyroxine Sodium26$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$143$19126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 pediatric endocrinology providers in Maryland.

Other pediatric endocrinology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →